載入...
Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement
PURPOSE: Papillary thyroid carcinomas (PTC) are the most common type of thyroid malignancy with one of the two mutations, RET/PTC rearrangement or BRAF mutation. Both mutations are able to activate the MEK/ERK signaling transduction pathway and result in the activation of transcription factors that...
Na minha lista:
| 發表在: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2008
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4420193/ https://ncbi.nlm.nih.gov/pubmed/18676765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-1772 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|